Prisinformation från TradingView

Bolagspresentation:

Nyhetsflöde Annexin Pharmaceuticals

Related articles:
10/18/2024 9:32:22 AM - Annexin Q3: Presented positive top-line data - Redeye - Redeye comments on Annexin's Q3 report and recent events in the company, most notably the top-line data presented in August.
8/22/2024 6:56:04 AM - Annexin: Positive top-line readout a derisk - Redeye - Redeye raises its base case following the positive readout in the phase IIa RVO study with ANXV.
8/21/2024 11:01:27 AM - Annexin: Positive top-line readout in phase IIa RVO trial - Redeye - Redeye gives an initial take on the positive phase IIa results in RVO with ANXV, an imporant milestone for the company.
7/19/2024 7:06:11 AM - Annexin Q2: RVO readout closing in - Redeye - Redeye comments on Annexin's Q2 report and recent events in the company. We note that interest in Annexin has increased rapidly lately following a strong outcome in the rights issue and upcoming phase II topline data in RVO with its drug candidate ANXV - and we expect an eventful summer/autumn ahead for the company.
5/31/2024 9:44:59 AM - Annexin: Full subscription in rights issue - Redeye - Redeye comments on the positive outcome of Annexin’s rights issue.
4/26/2024 8:20:33 AM - Annexin: Last patient in and additional readout confirms signal of effect - Redeye - Redeye endorses the latest progress with the ANXV phase II study in RVO and give our initial comment.
4/15/2024 10:56:52 AM - Annexin: Continued focus on RVO study - Redeye - Redeye returns with an update following Annexin’s Q1 report, which offered no surprises. We reiterate our positive stance and valuation for now.
4/3/2024 5:10:26 AM - Annexin: Announces rights issue - Redeye - Redeye comments on the news that Annexin has announced a rights issue of up to SEK45m.
2/12/2024 9:48:13 AM - Annexin Q4 2023: Continued RVO progress - Redeye - Redeye returns with an update following Annexin’s Q4 report, and the company continued to present advancements from its ongoing phase II study. We slightly raise our base case.
2/9/2024 9:25:48 AM - Annexin: Additional confirmation of effect signal and update on cash runway - Redeye - Redeye endorses yesterday's promising effect signal in 6 out of 8 patients followed for at least 3 months or longer in the ongoing phase II RVO study, showing no need for multiple doses of the standard of care anti-VEGFs, which we think is a good confirmation of the previous effect signal reported last year. In today’s report, the company mentioned that it has secured a loan facility from a few significant shareholders of up to SEK15m, which we think is reassuring given the company previously short cash runway. We will discuss the results and the report further in a research update to be published on Monday.
12/19/2023 12:52:37 PM - Annexin: Outcome of rights issue announced - Redeye - Redeye comments on Annexin’s rights issue's outcome and adjusts our valuation.
10/24/2023 9:31:57 AM - Annexin: Rights Issue Announced – We Pause Our Coverage - Redeye - Redeye briefly comments on Annexin Pharmaceuticals rights issue. We pause our coverage.
10/18/2023 2:47:04 PM - Annexin Q3 2023: Our Comment - Redeye - Redeye returns with an update following Annexin’s Q3 report. We note that it has been an eventful quarter for the company, including progress with its RVO and Cancer tracks. The report came in as expected but we expect the company to present a financing solution relatively soon.
9/29/2023 10:30:39 AM - Annexin: Preclinical progress with ANXV conjugate - Redeye - Redeye endorses today’s news that Annexin has reported preclinical progress with its approach to use ANXV as a drug conjugate, ie to deliver a chemotherapy agent specifically to the tumor with the goal to achieve a similar or better effect with reduced side effects. In today’s statement, the company reports that it has successfully produced a conjugate that also has been tested with initial promising results. While early, we are encouraged to see progress with this approach and hope to learn more about the way forward soon.
9/4/2023 8:36:58 AM - Annexin Pharmaceuticals vd kommenterar studieframgångarna - I mitten av augusti meddelade bioteknikbolaget Annexin Pharmaceuticals att man sett lovande effektsignaler i fas 2-studien med läkemedelskandidaten ANXV mot ögonsjukdomen retinal venocklusion (RVO). I en intervju med Finwire gav vd Anders Haegerstrand mer färg på studien och vägen framåt för bolaget.
8/13/2023 10:35:43 AM - Annexin: Initial signal of effect and tweaked design - Redeye - Redeye comments on today’s news that Annexin has seen initial signals of effect in the ongoing phase II RVO study and also made some modifications to the study design.
8/4/2023 9:52:59 AM - Annexin Q2’23: Eventful period ahead - Redeye - Redeye returns with an update following Annexin’s Q2 report. We note that the quarter was relatively uneventful but look forward to more newsflow in H2, most notably phase II RVO-data and a financing solution. We reiterate our base case for now.
6/2/2023 9:17:59 AM - Annexin Pharmaceuticals: RVO data on the horizon - Redeye - Redeye reviews the case of Annexin in the wake of the company’s Q1 report and recent newsflow. We conclude that 2023 will be an eventful year for the company, with initial phase II data in RVO potentially this summer.
4/18/2023 10:21:25 AM - Annexin: First results from Imaging Study in RVO - Redeye - Redeye is encouraged by the first report from Annexin’s imaging study (n=16), which indicates site-specific accumulation of ANXV in vessels affected by RVO in a patient, suggesting that ANXV reaches its target. The study will now continue, including in more patients and higher doses, to further substantiate this. In today’s release, Annexin also mentions that the study has been approved to include patients with diabetic retinopathy, which could give further insights, although is not the target indication for the moment. The trial is expected to be finalized by the end of 2023 and is thus run in tandem with the company’s ongoing phase II trial in RVO patients, where we expect initial data in H1 that could have a more significant impact on our valuation.
3/10/2023 9:34:24 AM - Annexin Pharmaceuticals: Strategy Update - Redeye - Annexin Pharmaceuticals' CEO, Anders Haegerstrand, Chief Scientific and Medical Officer, Anna Frostegård, and Head of Therapeutic Area Oncology, Alain Thibault, present the company’s strategic priorities and its commercial roll-out. Watch the replay from March 7.
3/6/2023 7:53:50 AM - Annexin Pharmaceuticals: Strategy Update - Redeye - Tomorrow between 13:00-15:00, Annexin Pharmaceuticals' CEO, Anders Haegerstrand, Chief Scientific and Medical Officer, Anna Frostegård, and Head of Therapeutic Area Oncology, Alain Thibault, will present the company’s strategic priorities and its commercial roll-out. After the presentation, Redeye's analyst will moderate a Q&A.
2/8/2023 11:50:26 AM - Annexin Q4: Important year ahead - Redeye - Redeye comments on Annexin’s Q4 report, which came in as expected, and largely reiterate our view of the company.
12/20/2022 7:50:43 AM - Annexin: Directed Issue confirms focus on Cancer - Redeye - Redeye gives a short comment on today’s news of a directed issue in Annexin, where the proceeds will be used to initiate a focus within cancer.
11/7/2022 8:21:43 AM - Annexin: Our Q3 Comment - Redeye - Redeye comments on Annexin’s Q3 report, which came in as expected, and largely reiterate our view of the company.
8/23/2022 2:13:34 PM - Annexin: Our Q2 Comment - Redeye - Redeye comments on today’s Q2 report from Annexin Pharmaceuticals and largely reiterate our view of the company.
6/21/2022 9:56:31 AM - Annexin Pharma: Directed Share Issue (As Expected) - Redeye - Yesterday evening, Annexin announced that it had decided on a directed share issue of SEK 10.9 million at SEK 0.88/share. This was expected and included in our valuation, as a group of major shareholders had committed to guarantee SEK 17 million in proceeds in relation to the company’s TO3 warrant program (which brough in SEK 6.1 million). We thus reiterate our base case of SEK 2.2 per share.
5/31/2022 8:33:24 AM - Annexin: Our Q1 Comment - Redeye - Redeye comments on yesterday’s Q1 report from Annexin Pharmaceuticals, which came in as expected.
5/5/2022 5:36:44 AM - Annexin Pharma: Outcome of Warrant Program Announced - Redeye - Redeye comments on yesterday’s announcement regarding the outcome of Annexin’s TO3 warrant program. We resume our coverage and slightly adjust our base case
4/5/2022 12:03:25 PM - Annexin Pharmaceuticals: Phase II Study approved to Start - Redeye - Redeye is encouraged by today’s news that Annexin’s phase II trial is approved to start in the US as well as by the overall positive momentum in the company. We give a short comment.
4/5/2022 7:48:08 AM - Annexin Pharmaceuticals: In-Licenses Patent Rights within Cancer - Redeye - We give a short comment on the news that Annexin Pharmaceuticals has in-licensed a patent related to the use of Annexin A5 in cancer.
3/30/2022 10:42:25 AM - Annexin: Strategy Update at Redeye - Redeye - Annexin Pharmaceuticals held a Strategy Update on the 30th of March. Check out the full replay in case you missed it.
2/3/2022 1:26:40 PM - Annexin Pharmaceuticals: Our Q4 Comment - Redeye - Redeye comments on Annexin’s Q4 report and summarize our view of 2021.
11/30/2021 1:33:31 PM - Annexin: Our Q3 Comment - Redeye - Redeye maintains our view of Annexin Pharmaceuticals and Base case of SEK 2.5 following the company’s report for the third quarter.
11/9/2021 12:14:30 PM - Annexin Pharmaceuticals: Our Comment on the Finalized Rights Issue - Redeye - We give our initial take on the completed rights issue in Annexin and adjust our base case.
9/22/2021 5:51:16 AM - Annexin: Rights Issue Announced– We Pause Our Coverage - Redeye - Redeye gives a short comment on the announced rights issue and pause our coverage.
9/15/2021 10:21:07 AM - Annexin Pharmaceuticals: ANXV Well Tolerated in Phase I study - Redeye - Annexin Pharmaceuticals announced yesterday positive results from its anticipated phase I study, a milestone for the company and its lead candidate ANXV. The market reaction was modest and we reiterate our stance that significant progress in the company largely has gone unnoticed. We raise our base case to SEK 4.5 (4) following the positive data.
8/19/2021 1:01:30 PM - Annexin Pharmaceuticals: Our Q2 Comment - Redeye - Redeye maintains our view of Annexin Pharmaceuticals and Base case of SEK 4 following the company’s report for the second quarter. We give a brief comment on the financials and the key events during and after the period.
5/26/2021 12:01:14 PM - Annexin Pharmaceuticals: Directed Issue of SEK 15 million Finalized - Redeye - Annexin Pharmaceuticals announced yesterday that the company had finalized a directed issue of SEK 15 million to four major shareholders, to finalize the ongoing ANXV phase I study. We give our comment on the transaction.
5/19/2021 2:11:04 PM - Annexin Pharmaceuticals: Investigator Initiated Covid-19 Study - Redeye - Annexin announced yesterday that the company is collaborating with a research team in the Netherlands to use its compound ANXV for Covid-19 in a study on moderate to severe patients. We give our initial comment.
5/6/2021 10:41:43 AM - Annexin Pharmaceuticals: Our Q1 Comment - Redeye - Redeye maintains our positive view of Annexin Pharmaceuticals and Base case of SEK 4 following the company’s report for the first quarter. We give a brief comment on the financials and the key events for the period.
5/5/2021 11:12:15 AM - Annexin Pharmaceuticals: Positive comments from regulatory authorities - Redeye - Redeye reiterates our positive view of Annexin Pharmaceuticals and lead candidate ANXV in retinal vein occlusion (RVO) following today’s announcement that the company has had successful meetings with a selection of regulatory authorities on the path to approval for ANXV (now in phase I). Given the innovative nature of Annexin’s treatment approach, we are pleased that regulators and Annexin are aligned at this stage. Our base case of SEK 4 offers a significant upside (100%) from today’s levels.
12/28/2020 6:37:59 AM - Annexin Pharmaceuticals styrelseordförande Carl-Fredrik Lindner ökar aktieinnehavet - Bioteknikbolaget Annexin Pharmaceuticals styrelseordförande Carl-Fredrik Lindner har den 23 december köpt 80 000 aktier i bolaget. Aktierna köptes till kursen 1,79 kronor per aktie, en affär på 143 000 kronor. Affären gjordes på First North. Det framgår av Finansinspektionens insynsregister.
12/21/2020 4:08:48 PM - Annexin Pharmaceuticals ANXV getts till människa för första gången - Bioteknikbolaget Annexin Pharmaceuticals läkemedelskandidat ANXV har getts till människa för första gången efter doseringsstart i bolagets fas 1-studie. Det framgår av ett pressmeddelande.
12/14/2020 7:41:16 AM - Annexin Pharmaceuticals säkrar konvertibellån inför kommande kliniska studier - Annexin Pharmaceuticals har tecknat avtal med ett konsortium om ett konvertibellån på 20 miljoner kronor. Det framgår av ett pressmeddelande.
12/10/2020 7:42:16 AM - Annexin Pharmaceuticals inleder samarbete kring imagingstudier för ANXV - Annexin Pharmaceuticals inleder ett studiesamarbete med forskningsbolaget Tracer för imagingstudier med läkemedelskandidaten ANXV inom retinal venocklusion (RVO). Det framgår av ett pressmeddelande.
11/25/2020 3:39:31 PM - Rekrytering av deltagare påbörjats i Annexin Pharmaceuticals fas 1-studie - Rekrytering av friska deltagare har inletts i Annexin Pharmaceuticals fas 1-studie med läkemedelskandidaten ANXV, efter grönt ljus från den nederländska myndigheten. Det framgår av ett pressmeddelande.
10/29/2020 7:37:53 AM - Annexin Pharmaceuticals redovisar som planerat små förändringar i resultatet - Annexin Pharmaceuticals redovisar som planerat ingen omsättning och små förändringar av resultatet.
10/1/2020 12:06:04 PM - Publikation pekar på möjlighet att behandla covid-19 med Annexins läkemedelskandidat ANXV - Professor Chris Reutelingsperger har tillsammans med medarbetare vid universitet i Maastricht, Nederländerna identifierat mekanismer som förefaller orsaka lungskador vid allvarlig covid-19 sjukdom och som kan hämmas av Annexins läkemedelskandidat ANXV.
9/22/2020 6:37:00 AM - Annexin Pharmaceuticals lämnar in ansökan för fas 1-studie i Nederländerna - Annexin Pharmaceuticals har anlitat ett bolag med en fas 1-klinik i Nederländerna för att genomföra den första studien i människa med sin läkemedelskandidat ANXV. Bolaget har även lämnat in prövningsansökan för fas 1-studien till den nederländska läkemedelsmyndigheten. Det framgår av ett pressmeddelande.
8/21/2020 7:09:37 AM - Annexin Pharmaceuticals förlust ökade i andra kvartalet - Annexin Pharmaceuticals redovisar en ökad förlust i det andra kvartalet och som väntat redovisas ingen omsättning.